Contact Us | Find Licensed Doctors - Genesis Regenerative

Request Our Educational Guide and Patient Testimonials

Thoracic Protocol Guidance

Specialties > Neurological > Thoracic

Among key components, should optimally include:

GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source – National Institute of Health > National Library of Medicine

Traumatic Brain Injury Protocol Guidance: 4 applications of 1 unit IV and 1 unit IN or CSF

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Parkinson’s Protocol Guidance

Specialties > Auto-Immune > Parkinson’s

Among key components, should optimally include:

IL6 – INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source – National Institute of Health > National Library of Medicine

Parkinson’s Protocol Guidance: 4 applications of 2 units IV

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Custom Protocol

Advanced Protocols > Custom Protocol

Among key components, should optimally include:
TNFRSF1B – TNF RECEPTOR SUPERFAMILY MEMBER 1B
PDB Code: 3ALQ
3D Model
Source – National Institute of Health > National Library of Medicine

Custom Protocol Guidance

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

COPD Protocol Guidance

Specialties > Pulmonary > COPD (Chronic Obstructive Pulmonary Disease)

Among key components, should optimally include:

FLT4 – FMS RELATED RECEPTOR TYROSINE KINASE 4
PDB Code: 4BSK
3D Model
Source – National Institute of Health > National Library of Medicine

COPD Protocol Guidance: 3 applications of 1 unit IV and 1 unit NEB

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Proactive Regeneration II – High-Stress Lifestyle

Specialties > Proactive Regeneration > High-Stress Lifestyle

Among key components, should optimally include:

GDF11 – GROWTH DIFFERENTIATION FACTOR 11
PDB Code: 5E4G
3D Model
Source – National Institute of Health > National Library of Medicine

Proactive Regeneration II Protocol Guidance: 1 application of 2 units IV monthly or bi-monthly

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Proactive Regeneration I – Common Lifestyle

Specialties > Proactive Regeneration > Common Lifestyle

Among key components, should optimally include:

GDF11 – GROWTH DIFFERENTIATION FACTOR 11
PDB Code: 5E4G
3D Model
Source – National Institute of Health > National Library of Medicine

Proactive Regeneration I Protocol Guidance: 1 application of 1 unit IV monthly

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Wrist Protocol Guidance

Specialties > Orthopedic > Wrist

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Wrist Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Thoracic Protocol Guidance

Specialties > Orthopedic > Thoracic

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Thoracic Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Stellate Ganglion Blocks Protocol Guidance

Specialties > Orthopedic > Stellate Ganglion Blocks

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Stellate Ganglion Blocks Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA + Nerve Block

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Shoulder Protocol Guidance

Specialties > Orthopedic > Shoulder

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Shoulder Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Lumbar Protocol Guidance

Specialties > Orthopedic > Lumbar

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Lumbar Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Knee Protocol Guidance

Specialties > Orthopedic > Knee

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Knee Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Hip Protocol Guidance

Specialties > Orthopedic > Hip

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Hip Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Hand Protocol Guidance

Specialties > Orthopedic > Hand

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Hand Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Ganglion Impair Protocol Guidance

Specialties > Orthopedic > Ganglion Impair

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Ganglion Impair Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA + Nerve Block

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Foot Protocol Guidance

Specialties > Orthopedic > Foot

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Foot Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Facet Joints Protocol Guidance

Specialties > Orthopedic > Facet Joints

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Facet Joints Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Elbow Protocol Guidance

Specialties > Orthopedic > Elbow

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Elbow Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Cervical Disks Protocol Guidance

Specialties > Orthopedic > Cervical Disks

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Cervical Disks Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Ankle Protocol Guidance

Specialties > Orthopedic > Ankle

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Ankle Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Macular Degeneration Protocol Guidance

Specialties > Ophthalmology > Macular Degeneration

Among key components, should optimally include:

NTF3 – NEUROTROPHIN 3
PDB Code: 3BUK
3D Model
Source – National Institute of Health > National Library of Medicine

Macular Degeneration Protocol Guidance: 3 applications of 2 units IV and 1 unit IN

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Thoracic Protocol Guidance

Specialties > Neurological > Thoracic

Among key components, should optimally include:

GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source – National Institute of Health > National Library of Medicine

Thoracic Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Stroke Protocol Guidance

Specialties > Neurological > Stroke

Among key components, should optimally include:

GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source – National Institute of Health > National Library of Medicine

Stroke Protocol Guidance: 4 applications of 1 unit IV and 1 unit IN or CSF

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Stellate Ganglion Blocks Protocol Guidance

Specialties > Neurological > Stellate Ganglion Blocks

Among key components, should optimally include:

GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source – National Institute of Health > National Library of Medicine

Stellate Ganglion Blocks Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA + Nerve Block

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Spinal Cord Injury Protocol Guidance

Specialties > Neurological > Spinal Cord Injury

Among key components, should optimally include:

GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source – National Institute of Health > National Library of Medicine

Spinal Cord Injury Protocol Guidance: 4 applications of 1 unit IV and 1 unit IN or CSF

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Peripheral Neuropathy Protocol Guidance

Specialties > Neurological > Peripheral Neuropathy

Among key components, should optimally include:

GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source – National Institute of Health > National Library of Medicine

Peripheral Neuropathy Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Depression/Addiction/Detox Protocol Guidance

Specialties > Neurological > Depression/Addiction/Detox

Among key components, should optimally include:

GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source – National Institute of Health > National Library of Medicine

Depression/Addiction/Detox Protocol Guidance: 4 applications of 1 unit IV and 1 unit IN or CSF

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Neurodegenerative Disorder Protocol Guidance

Specialties > Neurological > Neurodegenerative Disorder

Among key components, should optimally include:

GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source – National Institute of Health > National Library of Medicine

Neurodegenerative Disorder Protocol Guidance: 4 applications of 1 unit IV and 1 unit IN or CSF

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Lumbar Protocol Guidance

Specialties > Neurological > Lumbar

Among key components, should optimally include:

GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source – National Institute of Health > National Library of Medicine

Lumbar Protocol Guidance: 3 applications of 4cc IV and 4cc IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Ganglion Impair Protocol Guidance

Specialties > Neurological > Ganglion Impair

Among key components, should optimally include:

GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source – National Institute of Health > National Library of Medicine

Ganglion Impair Protocol Guidance: 3 applications of 4cc IV and 4cc IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Facet Joints Protocol Guidance

Specialties > Neurological > Facet Joints

Among key components, should optimally include:

GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source – National Institute of Health > National Library of Medicine

Facet Joints Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Cervical Discs Protocol Guidance

Specialties > Neurological > Cervical Discs

Among key components, should optimally include:

GDNF-GFRALPHA1 COMPLEX
PDB Code: 3FUB
3D Model
Source – National Institute of Health > National Library of Medicine

Cervical Discs Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Wounds Protocol Guidance

Specialties > Cosmetic > Wounds

Among key components, should optimally include:

EGFR – EPIDERMAL GROWTH FACTOR RECEPTOR
PDB Code: 7SI1
3D Model
Source – National Institute of Health > National Library of Medicine

Wounds Protocol Guidance: 3 applications of 1 unit IV and 1 unit SQ (per site)

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Ulcers Protocol Guidance

Specialties > Cosmetic > Ulcers

Among key components, should optimally include:

EGFR – EPIDERMAL GROWTH FACTOR RECEPTOR
PDB Code: 7SI1
3D Model
Source – National Institute of Health > National Library of Medicine

Ulcers Protocol Guidance: 3 applications of 1 unit IV and 1 unit SQ (per site)

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Neck Protocol Guidance

Specialties > Cosmetic > Neck

Among key components, should optimally include:

EGFR – EPIDERMAL GROWTH FACTOR RECEPTOR
PDB Code: 7SI1
3D Model
Source – National Institute of Health > National Library of Medicine

Neck Protocol Guidance: 3 applications of 1 unit IV and 1 unit SQ (per site)

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Leg Protocol Guidance

Specialties > Cosmetic > Leg

Among key components, should optimally include:

EGFR – EPIDERMAL GROWTH FACTOR RECEPTOR
PDB Code: 7SI1
3D Model
Source – National Institute of Health > National Library of Medicine

Leg Protocol Guidance: 3 applications of 1 unit IV and 1 unit SQ (per site)

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Skin Protocol Guidance

Specialties > Cosmetic > Skin

Among key components, should optimally include:

EGFR – EPIDERMAL GROWTH FACTOR RECEPTOR
PDB Code: 7SI1
3D Model
Source – National Institute of Health > National Library of Medicine

Skin Protocol Guidance: 3 applications of 1 unit IV and 1 unit SQ (per site)

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Hair Protocol Guidance

Specialties > Cosmetic > Hair

Among key components, should optimally include:

EGFR – EPIDERMAL GROWTH FACTOR RECEPTOR
PDB Code: 7SI1
3D Model
Source – National Institute of Health > National Library of Medicine

Hair Protocol Guidance: 3 applications of 1 unit IV and 1 unit SQ (per site)

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Face Protocol Guidance

Specialties > Cosmetic > Face

Among key components, should optimally include:

EGFR – EPIDERMAL GROWTH FACTOR RECEPTOR
PDB Code: 7SI1
3D Model
Source – National Institute of Health > National Library of Medicine

Face Protocol Guidance: 3 applications of 1 unit IV and 1 unit SQ (per site)

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Burns Protocol Guidance

Specialties > Cosmetic > Burns

Among key components, should optimally include:

EGFR – EPIDERMAL GROWTH FACTOR RECEPTOR
PDB Code: 7SI1
3D Model
Source – National Institute of Health > National Library of Medicine

Burns Protocol Guidance: 3 applications of 1 unit IV and 1 unit SQ (per site)

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Anti-Aging Protocol Guidance

Specialties > Cosmetic > Anti-Aging

Among key components, should optimally include:

GDF11 – GROWTH DIFFERENTIATION FACTOR 11
PDB Code: 5E4G
3D Model
Source – National Institute of Health > National Library of Medicine

Anti-Aging Protocol Guidance: 1 application of 2 units IV not less often than monthly

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Arm Protocol Guidance

Specialties > Cosmetic > Arm

Among key components, should optimally include:

EGFR – EPIDERMAL GROWTH FACTOR RECEPTOR
PDB Code: 7SI1
3D Model
Source – National Institute of Health > National Library of Medicine

Arm Protocol Guidance: 1 application of 2 units IV not less often than monthly

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Wrist Protocol Guidance

Specialties > Chiropractic > Wrist

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Wrist Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Thoracic Protocol Guidance

Specialties > Chiropractic > Thoracic

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Thoracic Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Stellate Ganglion Blocks Protocol Guidance

Specialties > Chiropractic > Stellate Ganglion Blocks

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Stellate Ganglion Blocks Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Shoulder Protocol Guidance

Specialties > Chiropractic > Shoulder

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Shoulder Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Lumbar Protocol Guidance

Specialties > Chiropractic > Lumbar

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Lumbar Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Knee Protocol Guidance

Specialties > Chiropractic > Knee

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Knee Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Hip Protocol Guidance

Specialties > Chiropractic > Hip

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Hip Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Hand Protocol Guidance

Specialties > Chiropractic > Hand

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Hand Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Ganglion Impair Protocol Guidance

Specialties > Chiropractic > Ganglion Impair

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Ganglion Impair Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Foot Protocol Guidance

Specialties > Chiropractic > Foot

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Foot Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Facet Joints Protocol Guidance

Specialties > Chiropractic > Facet Joints

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Facet Joints Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Elbow Protocol Guidance

Specialties > Chiropractic > Elbow

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Elbow Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Cervical Disks Protocol Guidance

Specialties > Chiropractic > Cervical Disks

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Cervical Disks Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Ankle Protocol Guidance

Specialties > Chiropractic > Ankle

Among key components, should optimally include:

BONE MORPHOGENETIC PROTEIN-7
PDB Code: 1BMP
3D Model
Source – National Institute of Health > National Library of Medicine

Ankle Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Vasculature Protocol Guidance

Specialties > Cardiological > Vasculature

Among key components, should optimally include:

VEGFA – VASCULAR ENDOTHELIAL GROWTH FACTOR A
PDB Code: 6ZFL
3D Model
Source – National Institute of Health > National Library of Medicine

Vasculature Protocol Guidance: 4 applications of 2 units IV

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Myocardial Infarction Protocol Guidance

Specialties > Cardiological > Myocardial Infarction

Among key components, should optimally include:

VEGFA – VASCULAR ENDOTHELIAL GROWTH FACTOR A
PDB Code: 6ZFL
3D Model
Source – National Institute of Health > National Library of Medicine

Myocardial Infarction Protocol Guidance: 4 applications of 2 units IV

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Peripheral Arterial Disease Protocol Guidance

Specialties > Cardiological > Peripheral Arterial Disease

Among key components, should optimally include:

VEGFA – VASCULAR ENDOTHELIAL GROWTH FACTOR A
PDB Code: 6ZFL
3D Model
Source – National Institute of Health > National Library of Medicine

Peripheral Arterial Disease Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- - Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
  - Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
  - Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
</ul class=”cutome-font”>
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Peripheral Neuropathy Protocol Guidance

Specialties > Cardiological > Peripheral Neuropathy

Among key components, should optimally include:

VEGFA – VASCULAR ENDOTHELIAL GROWTH FACTOR A
PDB Code: 6ZFL
3D Model
Source – National Institute of Health > National Library of Medicine

Peripheral Neuropathy Protocol Guidance: 3 applications of 1 unit IV and 1 unit IA

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Thyroid Protocol Guidance

Specialties > Auto-Immune > Thyroid

Among key components, should optimally include:

IL6 – INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source – National Institute of Health > National Library of Medicine

Thyroid Protocol Guidance: 4 applications of 2 units IV

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Rheumatoid Arthritis Protocol Guidance

Specialties > Auto-Immune > Rheumatoid Arthritis (RA)

Among key components, should optimally include:

IL6 – INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source – National Institute of Health > National Library of Medicine

Rheumatoid Arthritis Protocol Guidance: 4 applications of 2 units IV

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Multiple Sclerosis (MS) Protocol Guidance

Specialties > Auto-Immune > Multiple Sclerosis (MS)

Among key components, should optimally include:

IL6 – INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source – National Institute of Health > National Library of Medicine

Multiple Sclerosis Protocol Guidance: 4 applications of 2 units IV

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Irritable Bowel Syndrome Protocol Guidance

Specialties > Auto-Immune > Irritable Bowel Syndrome (IBS)

Among key components, should optimally include:

IL6 – INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source – National Institute of Health > National Library of Medicine

Irritable Bowel Syndrome Protocol Guidance: 4 applications of 2 units IV

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Hashimoto’s Protocol Guidance

Specialties > Auto-Immune > Hashimoto’s

Among key components, should optimally include:

IL6 – INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source – National Institute of Health > National Library of Medicine

Hashimoto’s Protocol Guidance: 4 applications of 2 units IV

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Fibromyalgia Protocol Guidance

Specialties > Auto-Immune > Fibromyalgia

Among key components, should optimally include:

IL6 – INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source – National Institute of Health > National Library of Medicine

Fibromyalgia Protocol Guidance: 4 applications of 2 units IV

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Diabetes Protocol Guidance

Specialties > Auto-immune > Diabetes

Among key components, should optimally include:

IL6 – INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source – National Institute of Health > National Library of Medicine

Diabetes Protocol Guidance: 4 applications of 2 units IV

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Crohn’s Protocol Guidance

Specialties > Auto-Immune > Crohn’s

Among key components, should optimally include:

IL6 – INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source – National Institute of Health > National Library of Medicine

Crohn’s Protocol Guidance: 4 applications of 2 units IV

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Autism (Non-Acute) Protocol Guidance

Specialties > Auto-Immune > Autism (Non-Acute)

Among key components, should optimally include:

IL6 – INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source – National Institute of Health > National Library of Medicine

Autism (Non-Acute) Protocol Guidance: 4 applications of 2 units IV

If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Ankle Protocol Guidance

Specialties > Auto-Immune > Autism (Acute)

Among key components, should optimally include:

IL6 – INTERLEUKIN 6
PDB Code: 1ALU
3D Model
Source – National Institute of Health > National Library of Medicine

Autism (Acute) Protocol Guidance: 4 applications of 2 units IV

*Lumbar puncture for severe older patients
If/as applicable, scaffolding optional but not necessary.
Applications spread over consecutive months unless otherwise specified by clinician.
Application of regenerative therapy commonly has a 3-stage effect over 1-6 months (or longer), depending on environment, genetics, and current health. Common progression as follows:
- Month 1 – release of proteins for immediate anti-inflammatory and initial regenerative catalysts.
- Months 2-4 – ongoing production and expression of proteins from mRNA (naturally occurring regenerative messages) for continued healing.
- Months 4-6+ – resident stem and niche quiescent progenitor cells recapitulate vitality, complete their mature phenotype from miRNA and continue the regeneration.
Variables in environment, lifestyle, pharmaceuticals and epigenetics can impact timing and results. Additional applications and adjusted dosages and/or frequency may be required based on such variables and the severity of indication(s).
Protocols are based on science and peer-reviewed publications with particularized emphasis on the established half-lives of each RNA and subsequent proteins they produce before reapplication is necessary.
Regenerative messages naturally process to areas of highest need first and induce a person’s own resident stem and niche quiescent progenitor cells to become and/or heal as they are meant to – for youthful stasis in cartilage, bone, muscle, nerve, adrenals, vasculature, lymphatic, lung, heart, kidney, liver, organs, etc.
Normal activity and pharmaceuticals at discretion of physician.

Protocol guidance is based on available science and peer-reviewed publications. Each clinician must follow their own protocol(s) based on peer-reviewed publications and professional expertise.

Request a Consultation

Find a Doctor